Thrombolytic therapy reduces red blood cell aggregation in plasma without affecting intrinsic aggregability

Thrombosis Research

Volumn 105, Issue 6, 2002, Pages 487-492

  Ben Ami, R ^a   Sheinman, G ^a   Yedgar, S ^b   Eldor, A ^a   Roth, A ^a   Berliner, A S ^a   Barshtein, G ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

Erythrocyte aggregation; Fibrinogen; Myocardial infarction; Plasminogen activators

Indexed keywords

ACETYLSALICYLIC ACID; D DIMER; DEXTRAN; DEXTRAN 500; FIBRINOGEN; HEPARIN DERIVATIVE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; HEPARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD RHEOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE AGGREGATION; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOGEN METABOLISM; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; INHIBITION KINETICS; MALE; METABOLITE; PLASMA; PRIORITY JOURNAL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY;

AGED; ASPIRIN; DEXTRANS; ERYTHROCYTE AGGREGATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HEPARIN; HUMAN; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; PLASMA; STREPTOKINASE; SUPPORT, NON-U.S. GOV'T; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; HUMANS; MIDDLE AGED;

EID: 0037085697     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00052-X     Document Type: Article

References (30)

1. Quantitative evaluation of flow dynamics of erythrocytes in microvessels: Influence of erythrocyte aggregation
2. Hemorrheologic changes following acute myocardial infarction
3. Rheological features of erythrocytes in acute myocardial infarction
4. Parameters of red blood cell aggregation as correlates of the inflammatory state
5. Involvement of erythrocyte aggregation and erythrocyte resistance to flow in acute coronary syndromes
6. Combined leukocyte and erythrocyte aggregation in patients with acute myocardial infarction
7. The effect of hemodilution on experimental myocardial infarction size
8. Observations on blood viscosity changes after acute myocardial infarction
9. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
10. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy
11. Lovastatin alters blood rheology in primary hyperlipoproteinemia: Dependence on lipoprotein(a)?
12. Effect of HMG-CoA reductase inhibitors on red blood cell membrane lipids and haemorheological parameters, in patients affected by familial hypercholesterolemia
13. Effects of ticlopidine on erythrocyte aggregation in thrombotic disorders
14. Intravenous ancrod for treatment of acute ischemic stroke. The STAT study: A randomized controlled trial
15. Altered rheological properties of blood following administration of tissue plasminogen activator and streptokinase in patients with acute myocardial infarction
16. Blood rheology in acute myocardial infarction: Effect of high-dose i.v. streptokinase compared to placebo
17. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions
18. Exposure of human platelets to plasmin results in the expression of irreversibly active fibrinogen receptors
19. Characterization of plasmin-induced platelet aggregation
20. Nomenclature and criteria for diagnosis of ischemic heart disease
21. Fibrinogen assays: A collaborative study of six different methods
22. Monitoring of red blood cell aggregability in a flow-chamber by computerized image analysis
23. Monitoring of erythrocyte aggregate morphology under flow by computerized image analysis
24. Mechanism of rouleaux formation
25. Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction
26. Physiological and pathophysiological significance of haemorheology
27. The possible role of hemorheology in atherothrombogenesis
28. O(2) release from erythrocytes flowing in a narrow O(2)-permeable tube: Effects of erythrocyte aggregation
29. Fibrinogen and C-reactive protein on admission as markers of final infarct size after primary angioplasty for acute myocardial infarction
30. Haemostatic variables and the outcome of myocardial infarction